Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

11.41
+0.24002.15%
Pre-market: 11.750.3389+2.97%07:19 EDT
Volume:3.73M
Turnover:42.48M
Market Cap:3.70B
PE:-20.91
High:11.69
Open:11.17
Low:10.90
Close:11.17
52wk High:12.58
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:0.99
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.13
PE(LYR):-23.28

Loading ...

AbCellera's Menopause Drug Reduces Hot Flashes in Mid-Stage Trial

Reuters
·
Aug 10

AbCellera Says Phase 2 Trial Shows Abcl635 Cuts Menopausal Hot Flashes After Single Dose

Reuters
·
Aug 10

Abcellera Biologics - Phase 2 Results Show Best-in-Class Reductions in Vasomotor Symptoms After Single Dose

THOMSON REUTERS
·
Aug 10

Abcellera Announces Positive Top-Line Phase 2 Clinical Trial Results for Abcl635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Abcl635 Demonstrates Favorable Tolerability Profile

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Abcl635 Significantly Improves Sleep and Patient Global Impression of Change

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Abcl635 Well-Tolerated with no Serious or Severe Adverse Events

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Study Meets Primary Efficacy Endpoints with Significant Reductions at Week 4

THOMSON REUTERS
·
Aug 10

AbCellera Biologics (ABCL) Is Up 21.4% After First Phase 2 Readout For Novel NK3R Antibody – Has The Bull Case Changed?

Simply Wall St.
·
Aug 09

AbCellera to Report Phase 2 Top-Line Data for Menopause Hot Flash Drug Abcl635 on Aug. 10

Reuters
·
Aug 08

Abcellera to Announce Top-Line Results from the Phase 2 Trial of Abcl635 for the Treatment of Moderate-to-Severe Vms Due to Menopause on Monday, August 10, 2026

THOMSON REUTERS
·
Aug 08

Piper Sandler Remains a Buy on AbCellera Biologics (ABCL)

TIPRANKS
·
Aug 07

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

Simply Wall St.
·
Aug 07

OmniAb Q2 Revenue Beats Analyst Estimates, Outlook Raised

Reuters
·
Aug 07

AbCellera Biologics is Maintained at Buy by Stifel

Dow Jones
·
Aug 06

AbCellera Biologics (ABCL) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 06

AbCellera Biologics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

AbCellera Q2 FY26 Net Loss Widens to USD 55.4 Million; Revenue Drops to USD 4.1 Million

Reuters
·
Aug 06

AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate

Benzinga Earnings
·
Aug 06

AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 Million

Reuters
·
Aug 06